Case Study 7 – Medialis generated a strategic manuscript highlighting the importance of weight in the management of Type 2 diabetes
The client promoted a medicine for the treatment of type 2 diabetes, one of the key secondary characteristics of which was its beneficial effect on weight.
Case Study 6 – Medialis successfully differentiated AZ (QW) GLP-1 within the GLP-1 class
Healthcare professionals (HCPs) are responsible for the selection of appropriate treatment for their patients.
Case Study 5 – Medialis differentiated GSK- ERA within the Endothelin Receptor Antagonist Class
Pulmonary arterial hypertension (PAH) is a disorder primarily of small pulmonary arteries which results in a progressive rise in pulmonary vascular resistance and right ventricular failure. It consist of 4 classes of increasing severity relating to exercise tolerance.
Case Study 4 – Medialis differentiated TKI -G within the tyrosine kinase class
There were three tyrosine kinase inhibitors approved for the treatment of EGFR+ve non small cell lung cancer.
The community were of the impression that there was no differentiation within this class and that TKI – A had the edge in terms of efficacy, even without any head-to-head data.
Three meta analyses were conducted, which showed that in terms of efficacy, the three members were indeed equivalent. Howeve,r no systematic review and meta analysis was conducted on the relative safety profiles of the members in the class.
Case Study 3 – Medialis differentiated Incobotulinum toxin within the botulinum toxin class
The botulinum toxin (BoNT-A) market comprised three main products.
The aesthetics indication was somewhat limited to the glabellar lines for all. The glabella was one of a possible 10 areas of the face that were currently being treated.
Promotion was limited due to regulatory constraints and there was a commonly held feeling that all three BoNTA’s were equivalent in efficacy and safety.
Case Study 2 – Medialis differentiated the Fentanyl Buccal Tablet within the Rapid Onset Opioid Class
The rapid onset opioid class was congested with three members, with little clear differentiation between them.
When considering that the BTcP market was still in need of building, this meant that several companies were competing for a relatively small number of patients.
Case Study 1 – Medialis built the Breakthrough Cancer Pain (BTcP) market
The Breakthrough Cancer Pain market is dwarfed by other pain markets, such as chronic pain.
The concept of BTcP was a relatively new one in that:
It was a specific type of cancer pain that was characterized by high insensity, short onset, short duration pain.